Microbiota and IPF: hidden and detected relationships Microbiota in IPF

Main Article Content

Alessio Fabbrizzi
Giulia Nannini
Federico Lavorini
Sara Tomassetti
Amedeo Amedei

Keywords

Idiopathic pulmonary fibrosis; Lung microbiota; Immune Response

Abstract

Lung microbiota (LM) is an interesting new way to consider and redesign pathogenesis and possible therapeutic approach to many lung diseases, such as idiopathic pulmonary fibrosis (IPF), which is an interstitial pneumonia with bad prognosis. Chronic inflammation is the basis but probably not the only cause of lung fibrosis and although the risk factors are not completely clear, endogenous factors (e.g. gastroesophageal reflux) and environmental factors like cigarette smoking, industrial dusts, and precisely microbial agents could contribute to the IPF development. It is well demonstrated that many bacteria can cause epithelial cell injuries in the airways through induction of a host immune response or by activating flogosis mediators following a chronic, low-level antigenic stimulus. This persistent host response could influence fibroblast responsiveness suggesting that LM may play a role in repetitive alveolar injury in IPF. We reviewed literature regarding not only bacteria but also the role of virome and mycobiome in IPF. In fact, some viruses such as hepatitis C virus or certain fungi could be etiological agents or co-factors in the IPF progress. We aim to illustrate how the cross-talk between different local microbiotas throughout specific axis and immune modulation governed by microorganisms could be at the basis of lung dysfunctions and IPF development. Finally, since the future direction of medicine will be personalized, we suggest that the analysis of LM could be a goal to research new therapies also in IPF.

Downloads

Download data is not yet available.
Abstract 319 | PDF Downloads 171

References

1. Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet. 2017;389(10082):1941–52.
2. Richeldi L, Rubin AS, Avdeev S, Udwadia ZF, Xu ZJ. Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Med. September 2015;13:237.
3. Duchemann B, Annesi-Maesano I, Jacobe de Naurois C, Sanyal S, Brillet P-Y, Brauner M, et al. Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris. Eur Respir J. Augustus 2017;50(2):1602419.
4. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18(7):1028–40.
5. Magnini D, Montemurro G, Iovene B, Tagliaboschi L, Gerardi RE, Lo Greco E, et al. Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies. Respiration. 2017;
6. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. Maart 2011;183(6):788–824.
7. Schwartz DA. Idiopathic Pulmonary Fibrosis Is a Genetic Disease Involving Mucus and the Peripheral Airways. Ann Am Thorac Soc. November 2018;15(Supplement_3):S192–7.
8. Invernizzi R, Wu BG, Barnett J, Ghai P, Kingston S, Hewitt RJ, et al. The Respiratory Microbiome in Chronic Hypersensitivity Pneumonitis Is Distinct from That of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. Julie 2020;203(3):339–47.
9. Monaghan H, Wells AU, Colby T V, du Bois RM, Hansell DM, Nicholson AG. Prognostic Implications of Histologic Patterns in Multiple Surgical Lung Biopsies From Patients With Idiopathic Interstitial Pneumonias. Chest. Februarie 2004;125(2):522–6.
10. Cottin V. Lung biopsy in interstitial lung disease: balancing the risk of surgery and diagnostic uncertainty. Eur Respir J. November 2016;48(5):1274 LP – 1277.
11. Tomassetti S, Wells AU, Costabel U, Cavazza A, Colby T V, Rossi G, et al. Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. November 2015;193(7):745–52.
12. Phillip JM, Aifuwa I, Walston J, Wirtz D. The Mechanobiology of Aging. Annu Rev Biomed Eng. Desember 2015;17(1):113–41.
13. Gulati S, Thannickal VJ. The Aging Lung and Idiopathic Pulmonary Fibrosis. Am J Med Sci. Mei 2019;357(5):384–9.
14. Lee JS. The Role of Gastroesophageal Reflux and Microaspiration in Idiopathic Pulmonary Fibrosis. Clin Pulm Med. Maart 2014;21(2):81–5.
15. Mitchell PD, Das JP, Murphy DJ, Keane MP, Donnelly SC, Dodd JD, et al. Idiopathic Pulmonary Fibrosis With Emphysema: Evidence of Synergy Among Emphysema and Idiopathic Pulmonary Fibrosis in Smokers. Respir Care. Februarie 2015;60(2):259 LP – 268.
16. Harari S, Caminati A. IPF: new insight on pathogenesis and treatment. Allergy. Mei 2010;65(5):537–53.
17. Tanjore H, Blackwell TS, Lawson WE. Emerging evidence for endoplasmic reticulum stress in the pathogenesis of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2012/01/27. April 2012;302(8):L721–9.
18. Kaur A, Mathai SK, Schwartz DA. Genetics in Idiopathic Pulmonary Fibrosis Pathogenesis, Prognosis, and Treatment. Front Med. September 2017;4:154.
19. Nogee LM, Dunbar AE, Wert SE, Askin F, Hamvas A, Whitsett JA. A Mutation in the Surfactant Protein C Gene Associated with Familial Interstitial Lung Disease. N Engl J Med. Februarie 2001;344(8):573–9.
20. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2007/08/30. 2008;40(3):362–82.
21. Mora AL, Rojas M, Pardo A, Selman M. Erratum: Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease. Nat Rev Drug Discov. 2017;16(11):810.
22. Friedman SL, Sheppard D, Duffield JS, Violette S. Therapy for Fibrotic Diseases: Nearing the Starting Line. Sci Transl Med. Januarie 2013;5(167):167sr1 LP-167sr1.
23. Heukels P, Moor CC, von der Thüsen JH, Wijsenbeek MS, Kool M. Inflammation and immunity in IPF pathogenesis and treatment. Respir Med. Februarie 2019;147:79–91.
24. Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J. November 2007;30(5):835 LP – 839.
25. Bueno M, Calyeca J, Rojas M, Mora AL. Mitochondria dysfunction and metabolic reprogramming as drivers of idiopathic pulmonary fibrosis. Redox Biol. 2020;(February):101509.
26. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. Mei 2011;377(9779):1760–9.
27. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al. Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis. N Engl J Med. September 2011;365(12):1079–87.
28. Inoue Y, Kaner RJ, Guiot J, Maher TM, Tomassetti S, Moiseev S, et al. Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype. Chest. 2020;
29. Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JI, Knight R. Bacterial community variation in human body habitats across space and time. Science. 2009/11/05. Desember 2009;326(5960):1694–7.
30. Zhao L. The tale of our other genome. Nature. Junie 2010;465:879.
31. Lederberg BJ, McCray AT. ’ Ome Sweet ’ Omics-- A Genealogical Treasury of Words. Sci. 2001;15(7):8.
32. Proctor LM. The human microbiome project in 2011 and beyond. Cell Host Microbe. 2011;10(4):287–91.
33. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature. 2011/04/20. Mei 2011;473(7346):174–80.
34. Aagaard K, Ma J, Antony KM, Ganu R, Petrosino J, Versalovic J. The Placenta Harbors a Unique Microbiome. Sci Transl Med. Mei 2014;6(237):237ra65 LP-237ra65.
35. Pearce MM, Hilt EE, Rosenfeld AB, Zilliox MJ, Thomas-White K, Fok C, et al. The female urinary microbiome: a comparison of women with and without urgency urinary incontinence. MBio. Julie 2014;5(4):e01283.
36. Frank DN, Feazel LM, Bessesen MT, Price CS, Janoff EN, Pace NR. The Human Nasal Microbiota and Staphylococcus aureus Carriage. PLoS One. Mei 2010;5(5):e10598.
37. Grice EA, Kong HH, Renaud G, Young AC, Program NCS, Bouffard GG, et al. A diversity profile of the human skin microbiota. Genome Res. Julie 2008;18(7):1043–50.
38. Traykova D, Schneider B, Chojkier M, Buck M. Blood Microbiome Quantity and the Hyperdynamic Circulation in Decompensated Cirrhotic Patients. PLoS One. Februarie 2017;12(2):e0169310–e0169310.
39. Dickson RP, Erb-Downward JR, Martinez FJ, Huffnagle GB. The Microbiome and the Respiratory Tract. Annu Rev Physiol. Februarie 2016;78(1):481–504.
40. Cui L, Morris A, Huang L, Beck JM, Twigg HL, Von Mutius E, et al. The microbiome and the lung. Annals of the American Thoracic Society. 2014.
41. Dickson RP, Erb-Downward JR, Huffnagle GB. Homeostasis and its Disruption in the Lung Microbiome. Am J Physiol - Lung Cell Mol Physiol. 2015;
42. Bassis CM, Erb-Downward JR, Dickson RP, Freeman CM, Schmidt TM, Young VB, et al. Analysis of the Upper Respiratory Tract Microbiotas as the Source of the Lung and Gastric Microbiotas in Healthy Individuals. Ravel J, redakteur. MBio. Mei 2015;6(2).
43. Wu H, Kuzmenko A, Wan S, Schaffer L, Weiss A, Fisher JH, et al. Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability. J Clin Invest. Mei 2003;111(10):1589–602.
44. Remot A, Descamps D, Noordine M-L, Boukadiri A, Mathieu E, Robert V, et al. Bacteria isolated from lung modulate asthma susceptibility in mice. Isme J. Januarie 2017;11:1061.
45. Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C, et al. Disordered microbial communities in asthmatic airways. PLoS One. Januarie 2010;5(1):e8578–e8578.
46. Aron-Wisnewsky J, Doré J, Clement K. The importance of the gut microbiota after bariatric surgery. Nat Rev Gastroenterol &Amp; Hepatol. Augustus 2012;9:590.
47. Dickson RP, Erb-Downward JR, Freeman CM, McCloskey L, Beck JM, Huffnagle GB, et al. Spatial Variation in the Healthy Human Lung Microbiome and the Adapted Island Model of Lung Biogeography. Ann Am Thorac Soc. Junie 2015;12(6):821–30.
48. Segal LN, Alekseyenko A V, Clemente JC, Kulkarni R, Wu B, Gao Z, et al. Enrichment of lung microbiome with supraglottic taxa is associated with increased pulmonary inflammation. Microbiome. Julie 2013;1(1):19.
49. Jung J-W, Choi J-C, Shin J-W, Kim J-Y, Park I-W, Choi BW, et al. Lung Microbiome Analysis in Steroid-Naїve Asthma Patients by Using Whole Sputum. Tuberc Respir Dis. Julie 2016;79(3):165–78.
50. Di Stefano A, Ricciardolo FLM, Caramori G, Adcock IM, Chung KF, Barnes PJ, et al. Bronchial inflammation and bacterial load in stable COPD is associated with TLR4 overexpression. Eur Respir J. Mei 2017;49(5).
51. Mathieu E, Escribano-Vazquez U, Descamps D, Cherbuy C, Langella P, Riffault S, et al. Paradigms of lung microbiota functions in health and disease, particularly, in asthma. Front Physiol. 2018;9(AUG):1–11.
52. Dang AT, Marsland BJ. Microbes, metabolites, and the gut–lung axis. Mucosal Immunol. 2019;12(4):843–50.
53. Wypych TP, Wickramasinghe LC, Marsland BJ. The influence of the microbiome on respiratory health. Nat Immunol. 2019;
54. Spagnolo P, Molyneaux PL, Bernardinello N, Cocconcelli E, Biondini D, Fracasso F, et al. The Role of the Lung’s Microbiome in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis. Int J Mol Sci. November 2019;20(22):5618.
55. Fabbrizzi A, Amedei A, Lavorini F, Renda T, Fontana G. The lung microbiome: clinical and therapeutic implications. Intern Emerg Med. November 2019;14(8):1241–50.
56. Langille MGI, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol. 2013/08/25. September 2013;31(9):814–21.
57. Fujimura KE, Sitarik AR, Havstad S, Lin DL, Levan S, Fadrosh D, et al. Neonatal gut microbiota associates with childhood multisensitized atopy and T cell differentiation. Nat Med. September 2016;22:1187.
58. Richardson H, Dicker AJ, Barclay H, Chalmers JD. The microbiome in bronchiectasis. Eur Respir Rev. September 2019;28(153):190048.
59. Mur LAJ, Huws SA, Cameron SJS, Lewis PD, Lewis KE. Lung cancer: A new frontier for microbiome research and clinical translation. Ecancermedicalscience. 2018;12:1–9.
60. Zhou H, Suo J, Zhu J. Therapeutic Relevance of Human Microbiota and Lung Cancer. Zhongguo Fei Ai Za Zhi. Julie 2019;22:464–9.
61. Nagano T, Otoshi T, Hazama D, Kiriu T, Umezawa K, Katsurada N, et al. Novel cancer therapy targeting microbiome. Onco Targets Ther. Mei 2019;12:3619–24.
62. Ahn HJ, Lee DS. Helicobacter pylori in gastric carcinogenesis. World J Gastrointest Oncol. 2015/12/15. Desember 2015;7(12):455–65.
63. Zheng Y, Fang Z, Xue Y, Zhang J, Zhu J, Gao R, et al. Specific gut microbiome signature predicts the early-stage lung cancer. Gut Microbes. April 2020;1–13.
64. Budden KF, Shukla SD, Rehman SF, Bowerman KL, Keely S, Hugenholtz P, et al. Functional effects of the microbiota in chronic respiratory disease. Lancet Respir Med. 2019;2600(18):1–14.
65. Molyneaux PL, Cox MJ, Willis-Owen SAG, Mallia P, Russell KE, Russell A-M, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. Oktober 2014;190(8):906–13.
66. Han MLK, Zhou Y, Murray S, Tayob N, Noth I, Lama VN, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: An analysis of the COMET study. Lancet Respir Med. 2014;
67. Salisbury ML, Han MK, Dickson RP, Molyneaux PL. Microbiome in interstitial lung disease: from pathogenesis to treatment target. Curr Opin Pulm Med. September 2017;23(5):404–10.
68. Faner R, Sibila O, Agustí A, Bernasconi E, Chalmers JD, Huffnagle GB, et al. The microbiome in respiratory medicine: Current challenges and future perspectives. Eur Respir J. 2017;49(4):1–12.
69. Molyneaux PL, Maher TM. The role of infection in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir Rev. September 2013;22(129):376 LP – 381.
70. Molyneaux PL, Maher TM. Respiratory microbiome in IPF: cause, effect, or biomarker? Lancet Respir Med. Julie 2014;2(7):511–3.
71. Huang Y, Ma S-F, Espindola MS, Vij R, Oldham JM, Huffnagle GB, et al. Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. Julie 2017;196(2):208–19.
72. Molyneaux PL, Willis-Owen SAG, Cox MJ, James P, Cowman S, Loebinger M, et al. Host-Microbial Interactions in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. Junie 2017;195(12):1640–50.
73. Hill S, Van Remmen H. Mitochondrial stress signaling in longevity: a new role for mitochondrial function in aging. Redox Biol. Julie 2014;2:936–44.
74. Nam H-S, Izumchenko E, Dasgupta S, Hoque MO. Mitochondria in chronic obstructive pulmonary disease and lung cancer: where are we now? Biomark Med. 2017/06/09. Mei 2017;11(6):475–89.
75. Saint-Georges-Chaumet Y, Attaf D, Pelletier E, Edeas M. Targeting microbiota-mitochondria inter-talk: Microbiota control mitochondria metabolism. Cell Mol Biol. 2015;61(4):121–4.
76. He Y, Wen Q, Yao F, Xu D, Huang Y, Wang J. Gut–lung axis: The microbial contributions and clinical implications. Crit Rev Microbiol. Januarie 2017;43(1):81–95.
77. Marsland BJ, Trompette A, Gollwitzer ES. The gut-lung axis in respiratory disease. Ann Am Thorac Soc. 2015;12(November):S150–6.
78. O’Dwyer DN, Ashley SL, Gurczynski SJ, Xia M, Wilke C, Falkowski NR, et al. Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis. Am J Respir Crit Care Med. Februarie 2019;199(9):1127–38.
79. Knippenberg S, Ueberberg B, Maus R, Bohling J, Ding N, Tort Tarres M, et al. <em>Streptococcus pneumoniae</em> triggers progression of pulmonary fibrosis through pneumolysin. Thorax. Julie 2015;70(7):636 LP – 646.
80. Friaza V, la Horra C de, Rodríguez-Domínguez MJ, Martín-Juan J, Cantón R, Calderón EJ, et al. Metagenomic analysis of bronchoalveolar lavage samples from patients with idiopathic interstitial pneumonia and its antagonic relation with Pneumocystis jirovecii colonization. J Microbiol Methods. 2010;82(1):98–101.
81. Takahashi Y, Saito A, Chiba H, Kuronuma K, Ikeda K, Kobayashi T, et al. Impaired diversity of the lung microbiome predicts progression of idiopathic pulmonary fibrosis. Respir Res. 2018;19(1):34.
82. Han MK, Zhou Y, Murray S, Tayob N, Noth I, Lama VN, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med. 2014/04/21. Julie 2014;2(7):548–56.
83. Ueda T, Ohta K, Suzuki N, Yamaguchi M, Hirai K, Horiuchi T, et al. Idiopathic Pulmonary Fibrosis and High Prevalence of Serum Antibodies to Hepatitis C Virus. Am Rev Respir Dis. Julie 1992;146(1):266–8.
84. Irving WL, Day S, Johnston IDA. Idiopathic Pulmonary Fibrosis and Hepatitis C Virus Infection. Am Rev Respir Dis. Desember 1993;148(6_pt_1):1683–4.
85. Moore BB, Moore TA. Viruses in Idiopathic Pulmonary Fibrosis. Etiology and Exacerbation. Ann Am Thorac Soc. November 2015;12 Suppl 2(Suppl 2):S186–92.
86. Tang Y-W, Johnson JE, Browning PJ, Cruz-Gervis RA, Davis A, Graham BS, et al. Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J Clin Microbiol. Junie 2003;41(6):2633–40.
87. Molyneaux P, James P, Cookson W, Moffatt M, Maher T. P062 The Role of the Fungal Microbiome in IPF . QJM An Int J Med. September 2016;109(suppl_1):S42–S42.
88. Varone F, Gibiino G, Gasbarrini A, Richeldi L. Evaluation of the lung microbiome as a therapeutic target in the management of idiopathic pulmonary fibrosis: Role of antioxidant/antibiotic combination therapy. Eur Rev Med Pharmacol Sci. 2019;23(14):6379–86.
89. Wang J, Lesko M, Badri MH, Kapoor BC, Wu BG, Li Y, et al. Lung microbiome and host immune tone in subjects with idiopathic pulmonary fibrosis treated with inhaled interferon-γ. ERJ Open Res. 2017;3(3):00008–2017.
90. Kondoh Y, Cottin V, Brown KK. Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir Rev. September 2017;26(145):170050.
91. Song JW, Hong S-B, Lim C-M, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. Februarie 2011;37(2):356 LP – 363.
92. Juarez MM, Chan AL, Norris AG, Morrissey BM, Albertson TE. Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies. J Thorac Dis. Maart 2015;7(3):499–519.
93. Network IPFCR, Raghu G, Anstrom KJ, King Jr TE, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012/05/20. Mei 2012;366(21):1968–77.
94. Fastrès A, Felice F, Roels E, Moermans C, Corhay J-L, Bureau F, et al. The Lung Microbiome in Idiopathic Pulmonary Fibrosis: A Promising Approach for Targeted Therapies. Int J Mol Sci. Desember 2017;18(12):2735.
95. HUIE TJ, OLSON AL, COSGROVE GP, JANSSEN WJ, LARA AR, LYNCH DA, et al. A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: Aetiology and outcomes. Respirology. Augustus 2010;15(6):909–17.
96. Oda K, Yatera K, Fujino Y, Ishimoto H, Nakao H, Hanaka T, et al. Efficacy of concurrent treatments in idiopathic pulmonary fibrosis patients with a rapid progression of respiratory failure: an analysis of a national administrative database in Japan. BMC Pulm Med. Junie 2016;16(1):91.
97. Shulgina L, Cahn AP, Chilvers ER, Parfrey H, Clark AB, Wilson ECF, et al. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax. Februarie 2013;68(2):155 LP – 162.
98. Anstrom KJ, Noth I, Flaherty KR, Edwards RH, Albright J, Baucom A, et al. Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy - the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial. Respir Res. Maart 2020;21(1):68.
99. Molyneaux PL, Cox MJ, Wells AU, Kim HC, Ji W, Cookson WOC, et al. Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis. Respir Res. Februarie 2017;18(1):29.
100. Park H, Shin JW, Park S-G, Kim W. Microbial Communities in the Upper Respiratory Tract of Patients with Asthma and Chronic Obstructive Pulmonary Disease. PLoS One. Oktober 2014;9(10):e109710.
101. Boem F, Amedei A. Healthy axis: Towards an integrated view of the gut-brain health. World J Gastroenterol [Internet]. 07 Augustus 2019;25(29):3838–41. Available at: https://pubmed.ncbi.nlm.nih.gov/31413521
102. Boem F, Nannini G, Amedei A. Not just ‘immunity’: how the microbiota can reshape our approach to cancer immunotherapy. Immunotherapy [Internet]. 01 April 2020;12(6):407–16. Available at: https://www.futuremedicine.com/doi/abs/10.2217/imt-2019-0192
103. Group NIHHMPW, Peterson J, Garges S, Giovanni M, McInnes P, Wang L, et al. The NIH Human Microbiome Project. Genome Res. Desember 2009;19(12):2317–23.
104. Bordenstein SR, Theis KR. Host Biology in Light of the Microbiome: Ten Principles of Holobionts and Hologenomes. PLoS Biol. Augustus 2015;13(8):e1002226–e1002226.
105. Huse SM, Ye Y, Zhou Y, Fodor AA. A core human microbiome as viewed through 16S rRNA sequence clusters. PLoS One. Junie 2012;7(6):e34242–e34242.
106. Chakravorty S, Helb D, Burday M, Connell N, Alland D. A detailed analysis of 16S ribosomal RNA gene segments for the diagnosis of pathogenic bacteria. J Microbiol Methods. 2007/02/22. Mei 2007;69(2):330–9.
107. Dickson RP, Erb-Downward JR, Prescott HC, Martinez FJ, Curtis JL, Lama VN, et al. Analysis of culture-dependent versus culture-independent techniques for identification of bacteria in clinically obtained bronchoalveolar lavage fluid. J Clin Microbiol. Oktober 2014;52(10):3605–13.

Most read articles by the same author(s)